- Home
- CHRS vs IPHA Comparison
CHRS vs IPHA Comparison
Compare CHRS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHRS | IPHA |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0M | 174.2M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CHRS | IPHA |
|---|---|---|
| Price | $1.36 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.51 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 1.1M | 21.7K |
| Earning Date | 11-06-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $277,728,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | $67.29 | $43.90 |
| P/E Ratio | $2.56 | ★ N/A |
| Revenue Growth | ★ 152.07 | N/A |
| 52 Week Low | $0.71 | $1.47 |
| 52 Week High | $1.89 | $3.51 |
Technical Indicators
Market Signals| Indicator | CHRS | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.56 | 42.81 |
| Support Level | $1.18 | $1.85 |
| Resistance Level | $1.35 | $1.91 |
| Average True Range (ATR) | 0.09 | 0.07 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 67.35 | 11.63 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.